Observational Study of Efanesoctocog Alfa Treatment Effects on Joint Health in People with Moderate to Severe Hemophilia A in Taiwan

What this Trial Is About

Researchers are conducting a national, multicenter, observational study in Taiwan to assess the effectiveness, safety, and use of efanesoctocog alfa as a preventive treatment for people with hemophilia A. This study gathers data both retrospectively from 12 to 24 months before starting efanesoctocog alfa and prospectively for up to five years during routine clinical visits. It includes joint imaging data for participants aged six years and older where available. The study observes participants who are already receiving efanesoctocog alfa prophylaxis as part of their usual care, without administering any treatment or requiring study-specific visits. Data collection includes joint ultrasound or MRI scans, clinical assessments, and treatment usage, with no interventions added by the study team. The study follows participants for five years after enrollment, with retrospective data collected for at least one year prior to treatment initiation. Participants contribute data through their regular clinical visits, where researchers record changes in joint health scores, bleeding rates, treatment adherence, and joint imaging results over time. The study also monitors hospitalizations, surgeries, and adverse events related to hemophilia A and its treatment. The total participation duration includes retrospective data and a five-year prospective follow-up, ending with the last participants final visit.

A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in Taiwan